BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.
“2013 was a transformative year for BIND as we made significant progress towards providing improved treatment options for patients with cancer,” said Scott Minick, BIND’s President and CEO.
Help employers find you! Check out all the jobs and post your resume.
